Today: 5 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Coca-Cola (KO) Stock After Hours on Dec. 12, 2025: Late Price Action, Key Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Coca-Cola (KO) Stock After Hours on Dec. 12, 2025: Late Price Action, Key Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Coca-Cola (KO) rose 2.04% to $70.52 on Dec. 12, 2025, defying a broad market selloff that saw the S&P 500 drop 1.1%. After-hours, KO edged down to about $70.25. Investors continued to digest news that COO Henrique Braun will succeed James Quincey as CEO in March 2026. Trading volume reached roughly 18.4 million shares.
13 December 2025
·
Nebius Group NV (NBIS) Stock After Hours on Dec. 12, 2025: What Happened, Latest News, Forecasts, and What to Watch Before the Next Market Open

Nebius Group NV (NBIS) Stock After Hours on Dec. 12, 2025: What Happened, Latest News, Forecasts, and What to Watch Before the Next Market Open

Nebius Group (NASDAQ: NBIS) shares fell 6.99% to $87.69 on Dec. 12, tracking a broader selloff in AI-related stocks after cautious earnings signals from major tech firms. After-hours trading was muted, with the stock edging down to $87.38. Volume reached about 14.6 million shares. U.S. markets will reopen Monday, Dec. 15.
13 December 2025
·
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer shares closed at $25.85 on Dec. 12, 2025, up 0.19%, and edged to $25.89 in after-hours trading. The company declared a $0.43 per-share dividend for Q1 2026. Trading volume reached 50.8 million shares during the session, with 1.56 million shares after hours. U.S. markets remain closed until Monday, Dec. 15.
13 December 2025
··
CrowdStrike (CRWD) Stock After Hours on Dec. 12, 2025: Key News, Analyst Forecasts, Insider Moves, and What to Watch Before the Next Market Open

CrowdStrike (CRWD) Stock After Hours on Dec. 12, 2025: Key News, Analyst Forecasts, Insider Moves, and What to Watch Before the Next Market Open

CrowdStrike shares closed at $504.78 on Dec. 12, down 2.49%, and traded near flat after hours at $504.15. The drop tracked a broader tech selloff as the S&P 500 and Nasdaq fell over 1%. Insider filings showed director Sameer K. Gandhi sold 1,879 shares on Dec. 9 under a pre-arranged plan. Trading volume reached about 2.6 million shares, slightly above average.
13 December 2025
··
KLA Corporation (KLAC) Stock After Hours (Dec. 12, 2025): Why Shares Fell 4% and What to Know Before the Next Market Open

KLA Corporation (KLAC) Stock After Hours (Dec. 12, 2025): Why Shares Fell 4% and What to Know Before the Next Market Open

KLA Corporation shares fell 4.19% to $1,193.92 on Friday, Dec. 12, 2025, snapping a five-day winning streak amid a broad semiconductor selloff. The stock touched an intraday low of $1,185.18 before stabilizing after hours, trading flat at $1,194.18 by 5:30 p.m. ET. No significant company-specific news emerged during the session.
13 December 2025
··
Warner Bros. Discovery (WBD) Stock After Hours on Dec. 12, 2025: Shares Hover Near $30 as Netflix–Paramount Bidding War Meets Antitrust Scrutiny — What to Know Next

Warner Bros. Discovery (WBD) Stock After Hours on Dec. 12, 2025: Shares Hover Near $30 as Netflix–Paramount Bidding War Meets Antitrust Scrutiny — What to Know Next

Warner Bros. Discovery closed at $29.98 on Dec. 12, 2025, slipping to $29.94 after hours as investors weighed Paramount’s $30 all-cash tender offer against Netflix’s lower bid for select assets. The stock’s narrow range reflects uncertainty over antitrust scrutiny and the outcome of both deals. Paramount’s offer expires Jan. 8, 2026, unless extended.
13 December 2025
·
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

European regulators on Dec. 12 recommended refusing marketing authorization for Anavex’s Alzheimer’s drug Blarcamesine, citing insufficient evidence of effectiveness, unresolved safety issues, and quality concerns. The EMA said Anavex may request re-examination within 15 days. Anavex shares, already volatile, moved sharply in early trading.
12 December 2025
·
Lemonade Stock (LMND) News Today: Tesla Car Connection, Insider Sales, and Analyst Targets in Focus on Dec. 12, 2025

Lemonade Stock (LMND) News Today: Tesla Car Connection, Insider Sales, and Analyst Targets in Focus on Dec. 12, 2025

Lemonade shares traded near $79 late Friday after touching the mid-$80s earlier in the week, following news of direct integration with Tesla cars for its auto insurance. Insider sale disclosures by senior executives and a director were reported. Analyst price targets remain mixed, with some below current trading levels. The stock showed volatility amid these developments.
12 December 2025
Goldman Sachs Stock (NYSE: GS) Today: Near Record Highs as 2026 Dealmaking Optimism Builds — December 12, 2025

Goldman Sachs Stock (NYSE: GS) Today: Near Record Highs as 2026 Dealmaking Optimism Builds — December 12, 2025

Goldman Sachs shares traded at $898.31 late Friday, down 1.4% after hitting a record high of $919.10 earlier this month. A senior executive told Reuters Japan’s M&A market is set for strong activity into 2026, with Goldman advising on major deals. The stock’s 52-week range spans $439.38 to $919.10. Analyst targets trail the current price, highlighting focus on future earnings surprises.
12 December 2025
·
Rocket Lab (RKLB) Stock Jumps as Neutron “Hungry Hippo” Clears a Key Milestone — Latest News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Rocket Lab (RKLB) Stock Jumps as Neutron “Hungry Hippo” Clears a Key Milestone — Latest News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Rocket Lab shares jumped about 10% Thursday after the company announced its Neutron rocket’s “Hungry Hippo” fairing cleared qualification testing. The fairing will ship to Virginia for Neutron’s first launch. An Electron launch was postponed for sensor checks, but investors focused on the Neutron milestone. Analyst commentary and recent launches have kept the stock in focus.
12 December 2025
····
Chipotle Stock (CMG) Rallies on 4,000th Restaurant Milestone: Today’s News, Analyst Forecasts, and the 2026 Outlook (Dec. 12, 2025)

Chipotle Stock (CMG) Rallies on 4,000th Restaurant Milestone: Today’s News, Analyst Forecasts, and the 2026 Outlook (Dec. 12, 2025)

Chipotle shares rose 3.6% to $36.13 on December 12 after opening its 4,000th restaurant in Manhattan, Kansas. The company marked the milestone by ringing the NYSE Opening Bell and reaffirmed plans for 315 to 345 new locations in 2025. Market cap stood near $52.5 billion. Analyst Bernstein maintained an Outperform rating.
12 December 2025
··
Pan American Silver Corp Stock (PAAS) News, Forecasts & Analysis — What’s Driving the Rally on December 12, 2025

Pan American Silver Corp Stock (PAAS) News, Forecasts & Analysis — What’s Driving the Rally on December 12, 2025

Pan American Silver (PAAS) shares closed at $49.59 on December 12, down 1.51%, near the top of their 52-week range after a strong year for silver prices. Silver hit a record $64.31 as the US dollar weakened following a Federal Reserve rate cut. Mirae Asset Global ETFs Holdings raised its PAAS stake by 15.5% in Q2, now holding about 2.88% of the company. Trading volume reached 19.48 million shares.
12 December 2025
··
First Majestic Silver (AG) Stock News Today (Dec. 12, 2025): Silver’s Record Run Fuels Volatility, Convertible Notes Refinancing, and Fresh Analyst Targets

First Majestic Silver (AG) Stock News Today (Dec. 12, 2025): Silver’s Record Run Fuels Volatility, Convertible Notes Refinancing, and Fresh Analyst Targets

First Majestic Silver shares fell to $15.77 Friday after opening near $17.15, swinging in a wide range as spot silver hit a record $64.64/oz before retreating to $63. The stock’s volatility follows a new $350 million convertible notes deal and silver’s surge after the Federal Reserve’s latest rate cut. AG set a 52-week high Thursday in the mid-$16s. Silver is up about 118% in 2025, according to Reuters.
12 December 2025
·
Wealthfront IPO: WLTH Debuts on Nasdaq After $485M Raise, Rings Opening Bell, and Tests Consumer Fintech Appetite

Wealthfront IPO: WLTH Debuts on Nasdaq After $485M Raise, Rings Opening Bell, and Tests Consumer Fintech Appetite

Wealthfront began trading on Nasdaq Friday after pricing its IPO at $14 per share, raising about $485 million and valuing the company near $2 billion. The Palo Alto-based robo-adviser sold 34.6 million shares, with 21.5 million from the company and the rest from existing holders. CEO David Fortunato and co-founders rang the Nasdaq Opening Bell in Times Square.
12 December 2025
··
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune shares traded around $5.29 at 16:50 UTC on Dec. 12, 2025, down 0.9% after a volatile session with heavy volume. The company is preparing for a CEO transition on Jan. 1, 2026, as investors await key pemvidutide Phase 2b data and an FDA meeting. Analyst targets and options activity are adding to the stock’s swings.
12 December 2025
··
1 … 470 471 472 473 474 … 587

Stock Market Today

  • Euronext Shares Rise Over 2%, Surpass Moving Averages in Paris Market
    June 5, 2026, 8:32 AM EDT. Euronext shares climbed more than 2% mid-session, outpacing other stocks on the CAC 40 index. The pan-European stock exchange operator continued the upward trend from the previous day, advancing above its short-term moving averages-a technical indicator showing recent price momentum. This positive momentum highlights growing investor confidence in Euronext amid a rising Paris market.

Latest articles

SmartKem Moves Higher Premarket as Volume Picks Up in Thinly Traded Nasdaq Listing

SmartKem Moves Higher Premarket as Volume Picks Up in Thinly Traded Nasdaq Listing

5 June 2026
SmartKem surged nearly 80% to $0.5753 in premarket trading Friday after closing up 11.5% at $0.3200, despite no new company news; the sub-$1 price keeps Nasdaq listing compliance and a possible reverse split in focus as shareholders prepare to vote June 23 on capital-structure changes, with the company warning of potential dilution and insufficient cash to fund operations for 12 months.
Nu Holdings Unveils $1 Billion Buyback; Investors Cautious

Nu Holdings Unveils $1 Billion Buyback; Investors Cautious

5 June 2026
Nu Holdings jumped 4.1% to $12.12 after announcing a $1 billion share buyback, but recent analyst downgrades and a CFO switch add uncertainty, with BofA cutting its target to $10 citing leadership transition risks; credit quality and growth spending remain key watch items as the buyback aims to support shares amid ongoing competitive and operational challenges.
Quantinuum slips premarket after $1.68 billion IPO debut

Quantinuum slips premarket after $1.68 billion IPO debut

5 June 2026
Quantinuum shares dropped 2.52% to $58.86 in premarket trading, slipping below their $60 IPO price after raising $1.68 billion in an upsized offering, as investors weigh early-stage financials—$5.2 million Q1 revenue against a $136.6 million net loss—and uncertainty over the company’s ability to turn quantum computing promise into repeatable commercial contracts.
Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

5 June 2026
Veru shares soared 88% to $4.23 after a Novo Nordisk deal to supply Wegovy free for Veru’s Phase 2b obesity study, with analysts calling it “external validation” and maintaining $24–$25 price targets, but risks remain as Veru keeps full rights to enobosarm and Novo can end the agreement with 60 days’ notice.
Go toTop